– Director Medicinal Chemistry and Preclinical Development
PhD, Pharmaceutical Chemistry, Oregon State University, 1997, BS, Chemistry, Willamette University, 1990, Current Role: Director of Chemistry and Preclinical Development, Joined Syntrix: 2002
Dr. Maeda has been with Syntrix for over 10 years, and during that time, has acted as lead medicinal chemist on a number of drug development projects. During his tenure, Dr. Maeda fostered key collaborations with prominent scientists in academia and industry to further preclinical development milestones. Dr. Maeda is the Principal Investigator on a multi-year SBIR grant from the National Heart, Lung and Blood Institute (NHLBI), which has led to the identification and preclinical advancement of SX-682 as a treatment for chronic obstructive pulmonary disease and bronchopulmonary dysplasia. Dr. Maeda was also responsible for the optimization of processes utilized in the synthesis of Phase II candidate, (L/D)-aminopterin. Dr. Maeda still leads preclinical lead optimization efforts at the bench, and he has over 20+ years of hands-on chemical research experience. As a supporter for chemical education, Dr. Maeda also closely oversees the Syntrix internship program, instructing select college students in the chemistry behind small molecule drug development. Dr. Maeda was an invited speaker at the 2013 NHLBI Regional Innovation Conference held in San Francisco.